Review





Similar Products

mtt cell proliferation assay kits  (ATCC)
97
ATCC mtt cell proliferation assay kits
Mtt Cell Proliferation Assay Kits, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mtt cell proliferation assay kits/product/ATCC
Average 97 stars, based on 1 article reviews
mtt cell proliferation assay kits - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
mtt solution  (Biotium)
95
Biotium mtt solution
Mtt Solution, supplied by Biotium, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mtt solution/product/Biotium
Average 95 stars, based on 1 article reviews
mtt solution - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
mtt cell proliferation assay  (ATCC)
97
ATCC mtt cell proliferation assay
Mtt Cell Proliferation Assay, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mtt cell proliferation assay/product/ATCC
Average 97 stars, based on 1 article reviews
mtt cell proliferation assay - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
3 4 5 dimethylthiazol 2 yl 2 5 diphenyltetrazolium  (Biotium)
95
Biotium 3 4 5 dimethylthiazol 2 yl 2 5 diphenyltetrazolium
Cell viability levels of SK‐BR‐3 and MCF‐7 determined by MTT assay. (A, B) Effects of single (A) and in combination (B) therapeutic agents on cell viability in HER2 + (SK‐BR‐3) and HER2 − (MCF‐7) breast cancer (BC) cell lines. The data is expressed as mean ± SD of three independent experiments ( N = 3). Statistical significance was determined by ANOVA followed by Dunnett's T3 post hoc test, where * p ‐value < 0.05; ** p ‐value < 0.01; *** p ‐value < 0.001 in comparison with the control group. (C) Experiments at the level of 3D cell lines, when incubated with D+T+P+N+I (Denosumab+Trastuzumab+Pertuzumab+Nivolumab+Ipilimumab) in HER2 + BC, resulted in a clinically significant reduction in cell viability, possibly through immunomodulation of the tumour microenvironment (TME), characterised by a marked increase in tumour‐infiltrating lymphocytes (TILs) infiltration and a possibly concurrent decrease in pro‐tumorigenic neutrophils (created using BioRender ( https://biorender.com/ )). ANOVA, analysis of <t>variance;</t> <t>MTT,</t> <t>3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium</t> bromide; SD, standard deviation.
3 4 5 Dimethylthiazol 2 Yl 2 5 Diphenyltetrazolium, supplied by Biotium, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3 4 5 dimethylthiazol 2 yl 2 5 diphenyltetrazolium/product/Biotium
Average 95 stars, based on 1 article reviews
3 4 5 dimethylthiazol 2 yl 2 5 diphenyltetrazolium - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
mtt cell viability assay kit  (Biotium)
95
Biotium mtt cell viability assay kit
Cell viability levels of SK‐BR‐3 and MCF‐7 determined by MTT assay. (A, B) Effects of single (A) and in combination (B) therapeutic agents on cell viability in HER2 + (SK‐BR‐3) and HER2 − (MCF‐7) breast cancer (BC) cell lines. The data is expressed as mean ± SD of three independent experiments ( N = 3). Statistical significance was determined by ANOVA followed by Dunnett's T3 post hoc test, where * p ‐value < 0.05; ** p ‐value < 0.01; *** p ‐value < 0.001 in comparison with the control group. (C) Experiments at the level of 3D cell lines, when incubated with D+T+P+N+I (Denosumab+Trastuzumab+Pertuzumab+Nivolumab+Ipilimumab) in HER2 + BC, resulted in a clinically significant reduction in cell viability, possibly through immunomodulation of the tumour microenvironment (TME), characterised by a marked increase in tumour‐infiltrating lymphocytes (TILs) infiltration and a possibly concurrent decrease in pro‐tumorigenic neutrophils (created using BioRender ( https://biorender.com/ )). ANOVA, analysis of <t>variance;</t> <t>MTT,</t> <t>3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium</t> bromide; SD, standard deviation.
Mtt Cell Viability Assay Kit, supplied by Biotium, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mtt cell viability assay kit/product/Biotium
Average 95 stars, based on 1 article reviews
mtt cell viability assay kit - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
mtt 3 4 5 dimethylthiazol 2yl 2 5 diphenyltetrazolium bromide  (Valiant Co Ltd)
94
Valiant Co Ltd mtt 3 4 5 dimethylthiazol 2yl 2 5 diphenyltetrazolium bromide
Cell viability levels of SK‐BR‐3 and MCF‐7 determined by MTT assay. (A, B) Effects of single (A) and in combination (B) therapeutic agents on cell viability in HER2 + (SK‐BR‐3) and HER2 − (MCF‐7) breast cancer (BC) cell lines. The data is expressed as mean ± SD of three independent experiments ( N = 3). Statistical significance was determined by ANOVA followed by Dunnett's T3 post hoc test, where * p ‐value < 0.05; ** p ‐value < 0.01; *** p ‐value < 0.001 in comparison with the control group. (C) Experiments at the level of 3D cell lines, when incubated with D+T+P+N+I (Denosumab+Trastuzumab+Pertuzumab+Nivolumab+Ipilimumab) in HER2 + BC, resulted in a clinically significant reduction in cell viability, possibly through immunomodulation of the tumour microenvironment (TME), characterised by a marked increase in tumour‐infiltrating lymphocytes (TILs) infiltration and a possibly concurrent decrease in pro‐tumorigenic neutrophils (created using BioRender ( https://biorender.com/ )). ANOVA, analysis of <t>variance;</t> <t>MTT,</t> <t>3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium</t> bromide; SD, standard deviation.
Mtt 3 4 5 Dimethylthiazol 2yl 2 5 Diphenyltetrazolium Bromide, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mtt 3 4 5 dimethylthiazol 2yl 2 5 diphenyltetrazolium bromide/product/Valiant Co Ltd
Average 94 stars, based on 1 article reviews
mtt 3 4 5 dimethylthiazol 2yl 2 5 diphenyltetrazolium bromide - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

Image Search Results


Cell viability levels of SK‐BR‐3 and MCF‐7 determined by MTT assay. (A, B) Effects of single (A) and in combination (B) therapeutic agents on cell viability in HER2 + (SK‐BR‐3) and HER2 − (MCF‐7) breast cancer (BC) cell lines. The data is expressed as mean ± SD of three independent experiments ( N = 3). Statistical significance was determined by ANOVA followed by Dunnett's T3 post hoc test, where * p ‐value < 0.05; ** p ‐value < 0.01; *** p ‐value < 0.001 in comparison with the control group. (C) Experiments at the level of 3D cell lines, when incubated with D+T+P+N+I (Denosumab+Trastuzumab+Pertuzumab+Nivolumab+Ipilimumab) in HER2 + BC, resulted in a clinically significant reduction in cell viability, possibly through immunomodulation of the tumour microenvironment (TME), characterised by a marked increase in tumour‐infiltrating lymphocytes (TILs) infiltration and a possibly concurrent decrease in pro‐tumorigenic neutrophils (created using BioRender ( https://biorender.com/ )). ANOVA, analysis of variance; MTT, 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide; SD, standard deviation.

Journal: Journal of Cellular and Molecular Medicine

Article Title: The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti‐HER2 Antibodies and Immunotherapy

doi: 10.1111/jcmm.71071

Figure Lengend Snippet: Cell viability levels of SK‐BR‐3 and MCF‐7 determined by MTT assay. (A, B) Effects of single (A) and in combination (B) therapeutic agents on cell viability in HER2 + (SK‐BR‐3) and HER2 − (MCF‐7) breast cancer (BC) cell lines. The data is expressed as mean ± SD of three independent experiments ( N = 3). Statistical significance was determined by ANOVA followed by Dunnett's T3 post hoc test, where * p ‐value < 0.05; ** p ‐value < 0.01; *** p ‐value < 0.001 in comparison with the control group. (C) Experiments at the level of 3D cell lines, when incubated with D+T+P+N+I (Denosumab+Trastuzumab+Pertuzumab+Nivolumab+Ipilimumab) in HER2 + BC, resulted in a clinically significant reduction in cell viability, possibly through immunomodulation of the tumour microenvironment (TME), characterised by a marked increase in tumour‐infiltrating lymphocytes (TILs) infiltration and a possibly concurrent decrease in pro‐tumorigenic neutrophils (created using BioRender ( https://biorender.com/ )). ANOVA, analysis of variance; MTT, 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide; SD, standard deviation.

Article Snippet: Following treatment, the reagent 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) (30006, Biotium Inc., Landing Parkway, Fremont, CA, USA) was added to each well at a final concentration of 0.5 mg/mL.

Techniques: MTT Assay, Comparison, Control, Incubation, Standard Deviation